EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Emergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023

Juliet Nkugwa Asio iD, Christine Watera iD, Grace Namayanja, Juliana de Fatima da Silva iD, Sherri Pals, Deogratius Ssemwanga iD, Grace Sanyu, Maria Nannyonjo, Usher Kabuga Kaganda, Ronald Busobozi, Hellen Nansumba iD, Miriam Nabukenya und 14 weitere

Open Forum Infectious Diseases · 26.11.2025 · 12 (12)

DOI: 10.1093/ofid/ofaf679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 06.11.2025. Verfasst von Juliet Nkugwa Asio und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Virology, Uganda Virus Research Institute (UVRI), Entebbe, Uganda. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIDS Relief, Centers for Disease Control and Prevention, PEPFAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As dolutegravir (DTG)-based regimens (DBRs) become more widely used and patients remain on treatment longer, cases of virological failure remain rare. This study presents findings from the second annual round of acquired HIV drug resistance (HIVDR) surveillance in Uganda, among individuals with viral nonsuppression (≥1000 copies/mL) receiving DBRs for ≥9 months. The first round was conducted from February to April 2022.

Methods

This nationally representative cross-sectional survey analyzed randomly selected remnant plasma and dried blood spot specimens collected between April and July 2023 from the Central Public Health Laboratories. Genotyping targeted the integrase, protease, and reverse transcriptase regions of the HIV-1 pol gene, resistance was analyzed using the Stanford HIVDR Database. Weighted HIVDR prevalence and 95% confidence intervals (CIs) were calculated for children (0–14 years) and adults (≥15 years).

Results

Out of 857 specimens tested, 400 (46.7%) were from children and 457 (53.3%) from adults. Median ages were 11 years for children and 36 years for adults. Median time on DBRs was 1.9 years for children and 2.4 years for adults. Five hundred and fifty-nine (65.2%) specimens were successfully genotyped. The prevalence of DTG resistance was 10.1% (95% CI: 6.4%–13.9%) in children and 8.6% (95% CI: 3.9%–13.3%) in adult, higher than the first round with a prevalence of 6.6% (95% CI: 3.5%–9.6%) and 4.4% (95% CI: 0.7%–7.1%), respectively Conclusions The increase in DTG resistance among both children and adults highlights the need to strengthen adherence and enhance early identification of individuals at risk of HIVDR through novel and existing programmatic interventions.

Schlagwörter

Stichwörter der Autor:innen

CADREUgandaacquired resistance to dolutegravir

Autor:innen und Institutionen

  • Department of General Virology, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
  • Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.
  • Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Medical Research Council (MRC)/UVRI & London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
  • Central Public Health Laboratories, Kampala, Uganda.
  • Ministry of Health, Kampala, Uganda.

ORCID-Profile: Juliet Nkugwa Asio, Christine Watera, Juliana de Fatima da Silva, Deogratius Ssemwanga, Hellen Nansumba, Alisen Ayitewala, Elliot Raizes, Du-Ping Zheng

Förderung

  • AIDS Relief
  • Centers for Disease Control and Prevention
  • PEPFAR

Zitieren

APA

Asio, J. N., Watera, C., Namayanja, G., da Silva, J. F., Pals, S., Ssemwanga, D., Sanyu, G., Nannyonjo, M., Kaganda, U. K., Busobozi, R., Nansumba, H., Nabukenya, M., Ayitewala, A., Ssali, M., Katureebe, C., Magongo, E. N., Balidawa, H., Nazziwa, E., Ntale, J., …, & Kaleebu, P. (2025). Emergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023. Open Forum Infectious Diseases, 12(12). https://doi.org/10.1093/ofid/ofaf679

Vancouver

Asio JN, Watera C, Namayanja G, da Silva JF, Pals S, Ssemwanga D, et al. Emergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023. Open Forum Infectious Diseases. 2025;12(12). doi:10.1093/ofid/ofaf679

BibTeX
@article{Asio2025,
  author = {Asio, Juliet Nkugwa and Watera, Christine and Namayanja, Grace and da Silva, Juliana de Fatima and Pals, Sherri and Ssemwanga, Deogratius and Sanyu, Grace and Nannyonjo, Maria and Kaganda, Usher Kabuga and Busobozi, Ronald and Nansumba, Hellen and Nabukenya, Miriam and Ayitewala, Alisen and Ssali, Mina and Katureebe, Cordelia and Magongo, Eleanor Namusoke and Balidawa, Hudson and Nazziwa, Esther and Ntale, Jonathan and Raizes, Elliot and Zheng, Du-Ping and Zeh, Clement and Hackett, Stephanie and Naluguza, Mary and Mbidde, Edward Katongole and Kaleebu, Pontiano},
  title = {Emergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {12},
  doi = {10.1093/ofid/ofaf679}
}
Kostenlos starten →